Extrawell Pharmaceutical Holdings
Market Cap
HK$353.7m
Last Updated
2021/04/17 10:23 UTC
Data Sources
Company Financials
Executive Summary
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. More Details
Rewards
Risk Analysis
Snowflake Analysis
Proven track record and fair value.
Share Price & News
How has Extrawell Pharmaceutical Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 858 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: 858's weekly volatility (11%) has been stable over the past year.
Market Performance
7 Day Return
-5.1%
858
-1.5%
HK Pharmaceuticals
0.7%
HK Market
1 Year Return
64.4%
858
18.8%
HK Pharmaceuticals
28.0%
HK Market
Return vs Industry: 858 exceeded the Hong Kong Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: 858 exceeded the Hong Kong Market which returned 28% over the past year.
Shareholder returns
| 858 | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.1% | -1.5% | 0.7% |
| 30 Day | -11.4% | -4.6% | -1.2% |
| 90 Day | 18.4% | 6.2% | 1.8% |
| 1 Year | 64.4%64.4% | 20.5%18.8% | 33.4%28.0% |
| 3 Year | -3.9%-3.9% | -11.0%-16.0% | 8.1%-3.9% |
| 5 Year | -52.3%-52.3% | 94.1%75.5% | 56.5%28.9% |
Long-Term Price Volatility Vs. Market
How volatile is Extrawell Pharmaceutical Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
What You Must Know About Extrawell Pharmaceutical Holdings Limited's (HKG:858) Beta Value1 year ago | Simply Wall St
Does Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO Pay Reflect Performance?2 years ago | Simply Wall St
Some Extrawell Pharmaceutical Holdings (HKG:858) Shareholders Have Taken A Painful 75% Share Price DropValuation
Is Extrawell Pharmaceutical Holdings undervalued compared to its fair value and its price relative to the market?
2.65x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 858's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 858's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 858 is good value based on its PE Ratio (2.7x) compared to the HK Pharmaceuticals industry average (12.6x).
PE vs Market: 858 is good value based on its PE Ratio (2.7x) compared to the Hong Kong market (11.8x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 858's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 858 is good value based on its PB Ratio (0.3x) compared to the HK Pharmaceuticals industry average (1.3x).
Future Growth
How is Extrawell Pharmaceutical Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
17.0%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Extrawell Pharmaceutical Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Extrawell Pharmaceutical Holdings performed over the past 5 years?
36.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 858 has a large one-off gain of HK$152.4M impacting its September 30 2020 financial results.
Growing Profit Margin: 858's current net profit margins are higher than last year (74%).
Past Earnings Growth Analysis
Earnings Trend: 858 has become profitable over the past 5 years, growing earnings by 36.1% per year.
Accelerating Growth: 858's earnings growth over the past year (112.2%) exceeds its 5-year average (36.1% per year).
Earnings vs Industry: 858 earnings growth over the past year (112.2%) exceeded the Pharmaceuticals industry 2.7%.
Return on Equity
High ROE: 858's Return on Equity (11.1%) is considered low.
Financial Health
How is Extrawell Pharmaceutical Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 858's short term assets (HK$212.0M) exceed its short term liabilities (HK$58.7M).
Long Term Liabilities: 858's short term assets (HK$212.0M) exceed its long term liabilities (HK$71.9M).
Debt to Equity History and Analysis
Debt Level: 858's debt to equity ratio (5.3%) is considered satisfactory.
Reducing Debt: 858's debt to equity ratio has increased from 4.9% to 5.3% over the past 5 years.
Debt Coverage: 858's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 858's interest payments on its debt are well covered by EBIT.
Balance Sheet
Dividend
What is Extrawell Pharmaceutical Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 858's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 858's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 858's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 858's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 858's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
12.5yrs
Average board tenure
CEO
Yi Xie (57 yo)
no data
Tenure
HK$1,386,000
Compensation
Dr. Yi Xie, Ph.D. serves as the Chief Executive Officer of Extrawell Pharmaceutical Holdings Ltd. Dr. Xie is one of the founders of United Gene group of companies in the PRC. Dr. Xie is responsible for res...
CEO Compensation Analysis
Compensation vs Market: Yi's total compensation ($USD178.44K) is about average for companies of similar size in the Hong Kong market ($USD227.72K).
Compensation vs Earnings: Yi's compensation has been consistent with company performance over the past year.
Board Members
Experienced Board: 858's board of directors are seasoned and experienced ( 12.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Extrawell Pharmaceutical Holdings Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Extrawell Pharmaceutical Holdings Limited
- Ticker: 858
- Exchange: SEHK
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$353.722m
- Shares outstanding: 2.39b
- Website: https://www.extrawell.com.hk
Number of Employees
Location
- Extrawell Pharmaceutical Holdings Limited
- Devon House
- Suites 2206-08, 22nd Floor
- Quarry Bay
- Hong Kong
Listings
Biography
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. It operates through Manufacturing, Tra...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/17 10:23 |
| End of Day Share Price | 2021/04/16 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.